<DOC>
	<DOCNO>NCT00079937</DOCNO>
	<brief_summary>A substance call immunoglobulin E ( IgE ) , naturally produce body , key role generate asthma attack . In patient allergy , exaggerated production IgE response specific substance pollen . Omalizumab new drug inactivate IgE . This study test safety efficacy omalizumab asthma attack child allergic asthma .</brief_summary>
	<brief_title>Efficacy Safety Omalizumab Children ( 6 - &lt; 12 Years ) With Moderate-severe , Inadequately Controlled Allergic Asthma</brief_title>
	<detailed_description>This study design provide one year efficacy safety data subcutaneous ( SC ) omalizumab , compare placebo child ( 6 &lt; 12 year ) moderate severe persistent asthma inadequate asthma control despite treatment accord National Heart , Lung Blood Institute ( NHLBI ) step 3 4 ( least medium dose inhaled corticosteroid without controller asthma medication ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : Parent legal guardian inform study procedure medication give write informed consent . Outpatient male female age 6 &lt; 12 year study entry , body weight 20 150 kg . Total serum IgE level ≥ 30 ≤ 1300 IU . Diagnosis allergic asthma ≥ 1 year duration , accord American Thoracic Society ( ATS ) criterion , screen history consistent clinical feature moderate severe persistent asthma accord National Heart Lung Blood Institute ( NHLBI ) guideline . Positive prick skin test least one perennial allergen , document within past 2 year take Screening . A radioallergosorbent test ( RAST ) could perform patient borderline skin prick test result consultation Novartis clinical personnel . Patients ≥ 12 % increase force expiratory volume 1 second ( FEV1 ) start value within 30 minute take 4 puff ( 4x100 µg ) salbutamol ( albuterol ) nebulized salbutamol 5 mg ( equivalent alternative B2agonist ) document within past year , screening , runin period , prior randomization . Patients take long acting B2agonist ( LABA ) medication within 12 hour reversibility test . Clinical feature moderate severe persistent asthma ( least step 3 ) despite therapy step 3 4 ( least medium dose inhale corticosteroid ( ICS ) fluticasone drypowder inhaler ( DPI ) ≥ 200 mg/day equivalent without controller medication ) . Documented history experience asthma exacerbation demonstrate inadequate symptom control last 4 week runin despite receive equivalent dose fluticasone DPI ≥ 200 mg/day total daily exvalve dose . Exclusion criterion : Patients receive systemic corticosteroid reason asthma , betaadrenergic antagonist route , anticholinergic within 24 hour Screening , methotrexate , gold salt , cyclosporin troleandomycin , receive desensitization therapy le 3 month stable maintenance dos prior Screening . Patients history food drug relate severe anaphylactoid anaphylactic reaction , history allergy antibiotic , aspirin nonsteroidal antiinflammatory drug ( NSAID ) relate asthma ( unless NSAID could avoid ) , active lung disease acute sinusitis/chest infection , elevate serum IgE level reason , presence/history clinically significant uncontrolled systemic disease , cancer , abnormal , electrocardiogram ( ECG ) previous month , platelet ≤ 100 x 109/L clinically significant laboratory abnormality Screening .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>allergic</keyword>
	<keyword>asthma</keyword>
	<keyword>atopic</keyword>
	<keyword>omalizumab</keyword>
	<keyword>immunoglobulin E</keyword>
	<keyword>IgE</keyword>
	<keyword>anti-IgE</keyword>
</DOC>